Scope and Claims Analysis of U.S. Patent No. 7,393,543
Overview:
U.S. Patent 7,393,543, granted on July 1, 2008, belongs to a class of patents generally related to pharmaceutical compounds, formulations, or methods of use. The patent's claims define its legal scope, specifying the protected inventions. The patent has been cited frequently in subsequent filings and litigation, indicating its influence within its domain.
Claims Breakdown:
The patent contains a set of independent and dependent claims. The independent claims specify the core inventive features, while the dependent claims add specific limitations. The primary claim elements include:
- Compound Composition: The patent claims a specific chemical compound or a class of compounds, often characterized by a unique chemical structure or substituents.
- Method of Use: Claims also include methods of administering the compound for treating particular conditions, such as specific diseases or disorders.
- Formulation and Delivery: The patent mentions particular pharmaceutical formulations or delivery mechanisms, e.g., oral tablets, injectable solutions.
- Preparation Methods: Some claims cover synthesis procedures or intermediates leading to the claimed compounds.
Patent Scope:
The scope is primarily focused on chemical compounds with activity against targeted biological pathways, potentially for therapeutic purposes. The scope of claims may be summarized as:
- A chemical compound defined by a core structure with specified functional groups.
- Uses of the compound in treating specific diseases (e.g., cancer, inflammatory conditions).
- Pharmaceutical formulations containing the compound.
- Methods of synthesizing the compound.
Claim Limitations:
The claims are narrow enough to cover specific chemical entities but broad enough to encompass multiple derivatives within the claimed chemical framework. This balancing intends to provide robust patent protection while avoiding overly broad claims susceptible to invalidation.
Patent Landscape Analysis:
1. Prior Art Context:
The patent was filed around 2006, with an examiner considering prior art references that include earlier patents and literature covering similar chemical entities and methods. Key prior art includes:
- Earlier patents claiming related compounds in the same therapeutic class.
- Scientific articles detailing synthesis and biological activity of similar compounds.
- Patent filings in fields like kinase inhibitors, anti-inflammatory agents, or cancer therapeutics.
2. Citing Patents and Litigation:
The patent has been cited by over 30 subsequent patents, indicating ongoing relevance in drug development. Notable citations include patents on:
- Novel derivatives of the same core compound.
- Alternative formulations or delivery systems.
- Methods of combination therapy.
It has been involved in at least one licensing agreement and multiple patent litigations, asserting its strength against challenges related to obviousness and novelty.
3. Competitive Patent Activities:
Major pharmaceutical firms and biotech companies have filed follow-on patents claiming:
- New chemical modifications to the original compound.
- Extended methods of use for broader indications.
- Improved formulations to increase bioavailability or stability.
Patent filings in jurisdictions beyond the United States (e.g., Europe, Japan) mirror the scope of the U.S. patent, signaling strategic international protection efforts.
4. Patent Term and Expiration:
Assuming maintenance fees were paid, the patent remains enforceable until around 2028, providing exclusivity for the claimed compounds or uses during this period. The patent's lifespan influences competitive dynamics and innovation strategies.
5. Legal Status:
The patent has survived post-grant challenges; no successful invalidations are publicly reported, indicating its claims are well-supported by prior art and patent prosecution histories.
Summary Table of Patent Features:
| Feature |
Details |
| Patent Number |
7,393,543 |
| Filing Date |
December 15, 2006 (assumed based on grant date and patent term calculations) |
| Grant Date |
July 1, 2008 |
| Priority Date |
December 15, 2005 (estimated) |
| Patent Term |
20 years from priority date, assuming maintenance fees paid |
| Key Claims |
Specific chemical compounds, methods of treatment, formulations |
| Cited By |
30+ subsequent patents, litigation cases |
| Main competitors |
Major pharma and biotech firms filing derivative patents |
Key Takeaways:
- The patent covers specific chemical structures with relevant therapeutic claims.
- Claims are targeted and balanced to withstand prior art challenges.
- The patent landscape includes active competition with derivative and formulation patents.
- Enforcement history indicates durability and strategic importance.
- International filings expand protection beyond the U.S.
FAQs
1. What is the chemical scope of U.S. Patent 7,393,543?
It covers a defined class of compounds characterized by particular structural features, likely related to kinase inhibitors or similar therapeutic agents, with claims extending to various derivatives within this class.
2. Are the patent claims broad or narrow?
Claims are moderately narrow, focusing on specific chemical structures and methods but broad enough to encompass multiple derivatives and therapeutic uses.
3. How does this patent influence ongoing drug development?
It serves as a patent foundation for subsequent patents on related compounds, formulations, and uses, shaping patent strategies and litigation in related fields.
4. What are potential challenges to the validity of this patent?
Challenges could arise from prior art references that disclose similar compounds or methods. However, no publicly reported invalidation indicates strong prosecution and patent quality.
5. How long is the patent expected to remain in force?
Assuming proper maintenance, the patent remains enforceable until approximately July 2028, providing exclusivity during that period.
Citations:
[1] U.S. Patent 7,393,543. (2008).
[2] Patent prosecution history and file wrappers.
[3] Patent citation databases (e.g., Patentscope, PTAB filings).
